The effects of mibefradil, a novel calcium channel antagonist on ventricular arrhythmias induced by myocardial ischemia and programmed electrical stimulation

Journal of Pharmacology and Experimental Therapeutics

Volumn 277, Issue 3, 1996, Pages 1517-1526

  Billman, George E ^a   Hamlin, Robert L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BUPIVACAINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DROPERIDOL PLUS FENTANYL; LIDOCAINE; MIBEFRADIL; MORPHINE SULFATE; PENTOBARBITAL; PROCAINAMIDE; TOCAINAMIDE; TOCAINIDE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CALCIUM CURRENT; CALCIUM TRANSPORT; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; EXERCISE; HEART ATRIOVENTRICULAR NODE; HEART LEFT VENTRICLE DP-DT; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE ISCHEMIA; HEART STIMULATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ARRHYTHMIA; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ELECTROCARDIOGRAPHY; HEART VENTRICLES; MIBEFRADIL; MYOCARDIAL ISCHEMIA; TETRAHYDRONAPHTHALENES; VERAPAMIL;

EID: 0030426282     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. 2+ channel antagonist mibefradil (RO 40-5967). Mol. Pharmacol. 48: 540-549, 1995.
2. BILLMAN, G. E.: Effect of calcium channel antagonists on susceptibility to sudden death: Protection from ventricular fibrillation. J. Pharmacol. Exp. Ther. 248: 1334-1342, 1989.
3. BILLMAN, G. E.: The antiarrhythmic and antifibrillatory effects of calcium antagonists. J. Cardiovasc. Pharmacol. 18: S107-S117, 1991.
4. BILLMAN, G. E.: The calcium channel antagonist flunarizine protects against ventricular fibrillation. Eur. J. Pharmacol. 212: 231-235, 1992a.
5. BILLMAN, G. E.: Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation. Eur. J. Pharmacol. 229: 179-187, 1992b.
6. BILLMAN, G. E.: Intracellular calcium chelator, BAPTA-AM, prevents cocaine-induced ventricular fibrillation. Am. J. Physiol. (Heart Circ. Physiol. 34) 265: H1529-H15354, 1993.
7. BILLMAN, G. E., MCILROY, B. AND JOHNSON, J. D.: Elevated myocardial calcium and its role in sudden cardiac death. FASEB J. 5: 2586-2592, 1991.
8. BILLMAN, G. E., SCHWARTZ, P. J., GAGNOL, J.-P., AND STONE, H. L.: The cardiac response to submaximal exercise in dogs susceptible to sudden cardiac death. J. Appl. Physiol. 69: 890-897, 1985.
9. BILLMAN, G. E., SCHWARTZ, P. J. AND STONE, H. L.: Baroreceptor reflex control of heart rate: A predictor of sudden cardiac death. Circulation 66: 874-880, 1982.
10. BODEN, W. E., KRONE, R. J., KLEIGER, R. E., OAKES, D., GREENBERG, H., DWYER, E. J., MILLER, J. P., ABRAMS, J., COPROMILAS, J., GOLDSTEIN, R., MOSS, A. J. AND THE MULTICENTER DILTIAZEM POSTINFARCTION TRIAL RESEARCH GROUP: Electrocardiographic subset analysis of diltiazem on long-term outcome after acute myocardial infarction. Am. J. Cardiol. 67: 336-342, 1991.
11. BUXTON, A. E., WAXMAN, H. L., MARCHLINSKI, F. E. AND JOSEPHSON, M. E.: Electropharmacology of nonsustained ventricular tachycardia: Effects of class I anti-arrhythmic agents, verapamil and propranolol. Am. J. Cardiol. 53: 738-744, 1984.
12. CLOZEL, J.-P., BANKEN, L. AND OSTERRIEDER, W.: Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J. Cardiovasc. Pharmacol. 14: 713-729, 1989.
13. CLOZEL, J.-P., OSTERRIEDER, W., KLEINBLOESEM, C. H., WELKER, H. A., SCHLAPPI, B., TUDOR, R., HEFTT, F., SCHMITT, R. AND EGGERS, H.: Ro 40-5967: A new nondihydropyridine calcium antagonist. Cardiovasc. Drug Rev. 9: 4-17, 1991.
14. 3H]desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc. Drugs Ther. 4: 731-936, 1990.
15. COLLINS, M. N. AND BILLMAN, G. E.: Autonomic response to coronary occlusion in animals susceptible to ventricular fibrillation. Am. J. Physiol. (Heart Circ. Physiol. 26) 257: H1886-1894, 1989.
16. EL-SHERIF, N., SCHERLAG, B. J., LAZZARA, R. AND HOPE, R. R.: Re-entrant arrhythmias in the late myocardial infarction period. 4. Mechanisms of action of lidocaine. Circulation 56: 395-402, 1977.
17. EZZAHER, A., BOUANANI, N. E. H., SU, S. B., HITTINGER, L. AND CROZATIER, B.: Increased negative inotropic effects of calcium-channel blockers in hypertrophied and failing rabbit heart. J. Pharmacol. Exp. Ther. 257: 466-471, 1991.
18. FABIATO, A.: Calcium-induced release of calcium from the sarcoplasmic reticulum. J. Gen. Physiol. 85: 189-195, 1985.
19. 2+ inward currents by Ro 40-5967 and verapamil: Relation to negative inotropy. Eur. J. Pharmacol. 196: 205-207, 1991.
20. GERSTENBLITH, G., SCHERLAG, B. J., HOPE, R. R. AND LAZZARA, R.: Lidocaine on conduction in ischemic His-Purkinje system of dogs. Am. J. Cardiol. 42: 587-591, 1978.
21. GILL, A., GLAIM, S. F., DAMIANO, B. P., SIT, S. P. AND BRANNAN, M. D.: Pharmacology of bepridil. Am. J. Cardiol. 69: 11D-16D, 1992.
22. GOMES, J. A. C., HARIMAN, R. I., KANG, P. S., EL-SHERIF, N., CHOWDHRY, I. AND LYONS, J.: Programmed electrical stimulation in patients with high-grade ventricular ectopy: Electrophysiologic findings and prognosis for survival. Circulation 70: 43-51, 1984.
23. HANSEN, J. F. AND THE DANISH STUDY GROUP ON VERAPAMIL IN MYOCARDIAL INFARCTION: Treatment with verapamil during and after an acute myocardial infarction: A review based on the Danish verapamil infarction trials I and II. J. Cardiovasc. Pharmacol. 18: suppl. 6, S20-S25, 1991.
24. HENSLEY, J., ALTSCHULD, R. A. AND BILLMAN, G. E.: Effects of calcium channel antagonists, verapamil, nifedipine, and Ro 40-5967, on intracellular free calcium transients in isolated adult canine ventricular myocytes. (Abstract) FASEB J. 8: A877, 1994.
25. HINE, L. K., LAIRD, N., HEWITT, P. AND CHALMWERS, M. D.: Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch. Intern. Med. 149: 2694-2698, 1989.
26. KASS, R. S. AND TSIEN, R. W.: Fluctuations in membrane current driven by intracellular calcium in cardiac Purkinje fibers. Biophys. J. 38: 259-269, 1982.
27. KIHARA, Y. AND MORGAN, J. P.: Intracellular calcium and ventricular fibrillation. Circ. Res. 68: 1378-1389, 1991.
28. KORETSUNE, Y. AND MARBAN, E.: Cell calcium in the pathophysiology of ventricular fibrillation and in the pathogenesis of postarrhythmic contractile dysfunction. Circulation 80: 369-379, 1989.
29. LAPPI, M. D. AND BILLMAN, G. E.: Effect of ryanodine on ventricular fibrillation induced by myocardial ischaemia. Cardiovasc. Res. 27: 2152-2159, 1993.
30. LEGATO, M. J.: The anatomic matrix as a factor in susceptibility to lethal arrhythmias in a canine model of sudden cardiac death. J. Mol. Cell. Cardiol. 25: 501-508, 1993.
31. LEVY, M. N.: Role of calcium in arrhythmogenesis. Circulation 80: suppl. IV, IV31-IV39, 1989.
32. LI, G.-R. AND FERRIER, G. R.: Effect of lidocaine on reperfusion arrhythmias and electrophysiological properties in an isolated ventricular muscle model of ischemia and reperfusion. J. Pharmacol. Exp. Ther. 257: 997-1004, 1991.
33. LYNCH, J. J., MONTGOMERY, D. G., VENTURA, A. AND LUCCHESI, B. R.: Antiarrhythmic and electrophysiologic effects of bepridil in chronically infarcted conscious dog. J. Pharmacol. Exp. Ther. 234: 72-80, 1985.
34. LYNCH, J. J., MONTGOMERY, D. G. AND LUCCHESI, B. R: The effects of calcium entry blockade on the vulnerability of infarcted canine myocardium toward ventricular fibrillation. J. Pharmacol. Exp. Ther. 239: 340-345, 1986.
35. MARBAN, E. AND WIER, W. G.: Ryanodine as a tool to determine the contributions of calcium entry and calcium release to the calcium transient and contraction of cardiac Purkinje fibers. Circ. Res. 56: 133-138, 1985.
36. MASON, J. W. AND THE ELECTROPHYSIOLOGICAL STUDY VERSUS ELECTROCARDIOGRAPHIC MONITORING INVESTIGATORS: A comparison of electrophysiological testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N. Eng. J. Med. 329: 445-451, 1993a.
37. MASON, J. W. AND THE ELECTROPHYSIOLOGICAL STUDY VERSUS ELECTROCARDIOGRAPHIC MONITORING INVESTIGATORS: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N. Eng. J. Med. 329: 452-458, 1993b.
38. MEHRA, R., ZEILER, R. H., GOUGH, W. B. AND EL-SHERIF, N.: Reentrant ventricular arrhythmias in the late myocardial infarction period. 9. Electrophysiologic anatomic correlation of reentrant circuits. Circulation 67: 11-24, 1983.
39. ++ channels. J. Pharmacol. Exp. Ther. 271: 1483-1488, 1994.
40. MERILLAT, J. C., LAKATTA, E. G., HANO, O. AND GUARNIERI, T.: Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ. Res. 67: 1115-1123, 1990.
41. 2+ channels by Ro 40-5967. Circ. Res. 75: 144-148, 1994.
42. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ. Res. 73: 777-782, 1993.
43. OPIE, L. H., NATHAN, D. AND LUBBE, W. F.: Biochemical aspects of arrhythmogenesis and ventricular fibrillation. Am. J. Cardiol. 43: 131-148, 1979.
44. 2+ channel blocker with potent vasodilator but weak inotropic action. J. Cardiovasc. Pharmacol. 13: 754-759, 1989.
45. RICHARDS, D. A. B., BYTH, K., ROSS, D. L. AND UTHER, J. B.: What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction? Circulation 83: 756-763, 1991.
46. SCHMITT, C., BRACHMANN, J., WALDECKER, H. B., SCHÖLS, W., BEYER, T. AND KÜBLER, W.: Electrophysiologic effects of bepridil in patients with refractory ventricular tachycardia assessed by programmed electrical stimulation. Clin. Cardiol. 13: 864-868, 1990.
47. SCHWARTZ, P. J., BILLMAN, G. E. AND STONE, H. L.: Autonomic mechanisms in ventricular fibrillation due to acute myocardial ischemia during exercise in dogs with healed myocardial infarction: An experimental model for sudden cardiac death. Circulation 69: 1182-1189, 1984.
48. 2+ channels are abnormal in genetically determined cardiomyopathetic hamster hearts. Circ. Res. 75: 149-155, 1994.
49. STEENBERGEN, C., LEVY, L., MURPHY, E. AND LONDON, R. E.: Elevations in cytosolic free calcium early in myocardial ischemia in perfused rat heart. Circ. Res. 60: 700-707, 1987.
50. STEINBECK, G., ANDRESEN, D., BACH, P., HABERL, R., OEFF, M., HOFFMANN, E. AND VON LEITNER, E.-R.: A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic sustained ventricular tachycardia. N. Eng. J. Med. 327: 987-992, 1992.
51. SUNG, R. J., SHAPIRO, W. A., SHEN, E. N., MORADY, F. AND DAVIS, J.: Effects of verapamil on ventricular tachycardias possibly caused by reentry, automaticity and triggered activity. J. Clin. Invest. 72: 350-360, 1983.
52. TEMESY-ARMOS, P. N., LEGENZA, M., SOUTHWORTH, S. R. AND HOFFMAN, B. F.: Effects of verapamil and lidocaine in a canine model of sudden coronary death. J. Am. Coll. Cardiol. 6: 674-681, 1985.
53. VÉNIANT, M., CLOZEL, J.-P. AND WOLFGANG, R.: Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J. Cardiovasc. Pharmacol. 17: 277-284, 1991.
54. WEBBER, D. J., LYNCH, J. J., MONTGOMERY, D. AND LUCCHESI, B. R.: Postinfarction sudden death: Significance of inducible ventricular tachycardia in a conscious canine model. Am. Heart J. 109: 8-18, 1985.
55. WELLENS, H. J. J., TAN, S. L., BAR, R. W. H., DUREN, D. R., LIE, K. I. AND DOHMEN, H. M.: Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal reentrant supraventricular tachycardia. Br. Heart J. 39: 1059-1066, 1977.
56. WIT, A. L. AND JANSE, M. J.: The Ventricular Arrhythmias of Ischemia and Infarctions: Electrophysiological Mechanisms. Future Publishing Co., Inc. Mount Kisco, NY, 1993.